Cytomegalovirus vaccines

Vaccines

Volumn , Issue , 2008, Pages 1147-1154

  Plotkin, Stanley A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80255139577     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3611-1.50046-5     Document Type: Chapter

References (129)

1. TH Weller (1971) The ctyomegaloviruses: Ubiquitous agents with protean clinical manifestations. N Engl J Med 285 267-274.
2. KB Fowler, S Stagno, RF Pass, et al. (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326 663-667.
3. S Stagno, RF Pass, G Cloud, et al. (1986) Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 256 1904-1908.
4. WD Williamson, MM Desmond, N LaFevers, et al. (1982) Symptomatic congenital cytomegalovirus. Disorders of language, learning, and hearing. Am J Dis Child 136 902-905.
5. JB Hanshaw (1971) Congenital cytomegalovirus infection: a fifteen year perspective. J Infect Dis 123 555-561.
6. KB Fowler, S Stagno and RF Pass (2003) Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289 1008-1011.
7. MG Revello and G Gerna (2002) Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 15 680-715.
8. SP Adler (1996) Current prospects for immunization against cytomegaloviral disease. Infect Agents Dis 5 29-35.
9. L Pereira, E Maidji, S McDonagh and T Tabata (2005) Insights into viral transmission at the uterine-placental interface. Trends Microbiol 13 164-174.
10. A Porath, RA McNutt, LM Smiley and KA Weigle (1990) Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease. Rev Infect Dis 12 31-40.
11. SA Plotkin (2001) Vaccines in the 21st century. Infect Dis Clin North Am 15 307-327.
12. JL Melnick, E Adam and ME DeBakey (1995) Cytomegalovirus and atherosclerosis. BioEssays 17 899-903.
13. JF Nieto, E Adam, P Sorlie, et al. (1996) Cohort study of cytomegalovirus iinfection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 94 922-927.
14. K Berencsi, V Endresz, D Klurfeld, K Laszlo, et al. (1998) Early atherosclerotic plaques in the aorta following cytomegalovirus infection of mice. Cell Adhesion and Comm 5 39-47.
15. MC Persoons, MJ Daemen, JH Bruning and CA Bruggeman (1994) Active cytomegalovirus infection of arterial smooth muscle cells in immunocompromised rats. A clue to herpesvirus-associated atherogenesis. Circ Res 75 214-220.
16. YF Zhou, MB Leon, MA Waclawiwq, et al. (1996) Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 35 624-630.
17. E Speir, R Modali, ES Huang, et al. (1994) Potential role of human cytomegalvorius and p53 interaction in coronary restenosis. Science 265 391-394.
18. ME Falagas, DR Snydman, J Griffith, et al. (1997) Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Ann Intern Med 126 275-279.
19. J Glenn (1981) Cytomegalovirus infections following renal transplantation. Rev Infect Dis 3 1151-1178.
20. DJ Winston, WG Ho and RE Champlin (1990) Cytomegalovirus infections after allogeneic bone marrow transplanation. Rev Infect Dis 12 S776-S792.
21. J Zanten, L Leij, J Prop, et al. (1998) Human cytomegalovirus: a viral complication in transplantation. Clin Transplant 12 145-158.
22. J Mintz, L Leij and J Prop (1983) Cytomegalovirus infections in homosexual men. Ann Intern Med 99 326-329.
23. Q Ouyang, WM Wagner, W Zheng, et al. (2004) Dysfunctional CMV-specific CD8(+) T cells accumulate in the elderly. Exp Gerontol 39 607-613.
24. P Trzonkowski, J Mysliwska, E Szmit, et al. (2004) Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination–an impact of immunosenescence. Vaccine 21 3826-3836.
25. SR Riddell, MJ Gilbert, CR Li, BA Walter and PD Greenberg (1993) Reconstitution of protective CD8+ cytotoxic T lymphocyte responses to human cytomegalovirus in immunodeficient humans by the adoptive transfer of T cell clones. S Michelson, SA Plotkin (Eds) Multidisciplinary approach to understanding cytomgegalovirus disease Paris: Elsevier Science Publications
26. EA Walter, PD Greenberg, MJ Gilbert, et al. (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor [see comments]. N Engl J Med 333 1038-1044.
27. R Khanna and DJ Diamond (2006) Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med 12 26-33.
28. DR Snydman, BG Werner, B Heinze-Lacey, et al. (1987) Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317 1049-1054.
29. DR Snydman (1990) Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev Infect Dis 12(Suppl 7), S839-S848.
30. DR Snydman (1991) Prevention of cytomegalovirus-associated diseases with immunoglobulin. Transplant Proc 23(Suppl 3), 131-135.
31. BG Werner, DR Snydman, R Freeman, et al. (1993) Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. Transplant Proc 25 1441-1443.
32. DR Snydman, BG Werner, NN Dougherty, et al. (1993) Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 119 984-991.
33. JD Meyers (1991) Critical evaluation of agents used in the treatment and prevention of cytomegalovirus infection in immunocompromised patients. Transplant Proc 23 139-142. discussion.
34. D Emanuel, I Cunningham, K Jules-Elysee, et al. (1988) Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 109 777-782.
35. AS Yeager, FC Grumet, EB Hafleigh, et al. (1981) Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 98 281-287.
36. SP Adler, T Chandrika, L Lawrence and J Baggett (1983) Cytomegalovirus infections in neonates acquired by blood transfusions. Pediatr Infect Dis 2 114-118.
37. DF Bratcher, N Bourne, FJ Bravo, et al. (1995) Effect of passive antibody on congenital cytomegalovirus infection in Guinea pigs. J Infect Dis 172 944-950.
38. A Chatterjee, CJ Harrison, WJ Britt and C Bewtra (2001) Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs. J Infect Dis 183 1547-1553.
39. KS Erlich, J Mills and JD Shanley (1989) Effects of L3T4+ lymphocyte depletion on acute murine cytomegalovirus infection. J Gen Virol 70(Pt 7), 1765-1771.
40. UH Koszinowski, M Del Val and MJ Reddehase (1990) Cellular and Molecular Basis of the Protective Immune Response to Cytomegalovirus Infection. Curr Top Cell Regul 154 189-220.
41. GV Quinnan Jr, N Kirmani, AH Rook, et al. (1982) Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 307 7-13.
42. P Reusser, SR Ridell, JD Meyers and D Greenberg (1991) Cytotoxic T-lymphocyte response to cytomegalovirus after human allogenic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78 1373-1380.
43. G Nigro, SP Adler, R La Torre and AM Best (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353 1350-1362.
44. SP Adler and G Nigro (2006) Interrupting intrauterine transmission of cytomegalovirus. Rev Med Virol 16 1-4.
45. MR Schleiss, N Bourne, G Stroup, et al. (2004) Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis 189 1374-1381.
46. E Maidji, S McDonagh, O Genbacev, et al. (2006) Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am J Pathol 168 1210-1226.
47. M Bodeus and P Goubau (1999) Predictive value of maternal-IgG avidity for congenital human cytomegalovirus infection. J Clin Virol 12 3-8.
48. W Tu, S Chen, M Sharp, et al. (2004) Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol 172 3260-3267.
49. LE Gamadia, EB Remmerswaal, JF Weel, et al. (2003) Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 101 2686-2692.
50. L Gibson, G Piccinini, D Lilleri, et al. (2004) Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection. J Immunol 172 2256-2264.
51. SF Chen, WW Tu, MA Sharp, et al. (2004) Antiviral CD8 T cells in the control of primary human cytomegalovirus infection in early childhood. J Infect Dis 189 1619-1627.
52. Z Gyulai, V Endresz, K Burian, et al. (2000) Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 181 1537-1546.
53. T Bunde, A Kirchner, B Hoffmeister, et al. (2005) Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201 1031-1036.
54. SD Elek and H Stern (1974) Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1 1-5.
55. SA Plotkin, T Furukawa, N Zygraich and C Huygelen (1975) Candidate cytomegalovirus strain for human vaccination. Infect Immun 12 521-527.
56. SA Plotkin, J Farquhar and E Hornberger (1976) Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J Infect Dis 134 470-475.
57. SA Plotkin and C Huygelen (1976) Cytomegalovirus vaccine prepared in WI-38. Dev Biol Stand 37 301-305.
58. Y Yamane, T Furukawa and SA Plotkin (1983) Supernatant virus release as a differentiating marker between low passage and vaccine strains of human cytomegalovirus. Vaccine 1 23-25.
59. G Gerna, F Baldanti and MG Revello (2004) Pathogenesis of human cytomegalovirus infection and cellular targets. Hum Immunol 65 381-386.
60. M Just, A Buergin-Wolff, G Emoedi and R Hernandez (1975) Immunisation trials with live attenuated cytomegalovirus TOWNE 125. Infection 3 111-114.
61. SA Plotkin (1999) Cytomegalovirus vaccine. Am Heart J 138 484. 187
62. GR Fleisher, SE Starr, HM Friedman and SA Plotkin (1982) Vaccination of pediatric nurses with live attenuated cytomegalovirus. Am J Dis Child 136 294-296.
63. GVJ Quinnan, M Delery, AH Rook, et al. (1984) Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann Intern Med 101 478-483.
64. SP Adler, S Hempfling, S Starr, et al. (1998) Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Ped Infect Dis J 17 200-206.
65. SE Starr, JP Glazer, HM Friedman, et al. (1981) Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine. J Infect Dis 143 585-589.
66. WP Carney, MS Hirsch, VR Iacoviello, et al. (1983) T-lymphocyte subsets and proliferative responses following immunization with cytomegalovirus vaccine. J Infect Dis 147 958.
67. MA Jacobson, E Sinclair, B Bredt, et al. (2006) Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J Clin Virol 35 332-337.
68. AD Friedman, T Furukawa and SA Plotkin (1982) Detection of antibody to cytomegalovirus early antigen in vaccinated, normal volunteers and renal transplant candidates. J Infect Dis 146 255-259.
69. AD Friedman, S Michelson and SA Plotkin (1982) Detection of antibodies to pre-early nuclear antigen and immediate-early antigens in patients immunized with cytomegalovirus vaccine. Infect Immun 38 1068-1072.
70. SA Plotkin (1984) CMV vaccines. Bull WHO 5 96-109.
71. RE Burns, RB Brennan, RG Douglas and TE Talley (1977) Clinical manifestations of renal allograft-derived primaryh cytomegalovirus infection. Am J Dis Child 131 759-763.
72. RF Pass, WK Long, RJ Whitley, et al. (1978) Productive infection with cytomegalovirus and herpes simplex virus in renal transplant recipients: role of source of kidney. J Infect Dis 137 556-563.
73. S Suwansirikul, N Rao, JN Dowling and M Ho (1977) Primary and secondary cytomegalovirus infection. Arch Intern Med 137 1026-1029.
74. SA Plotkin, ML Smiley, HM Friedman, et al. (1984) Prevention of cytomegalovirus disease by Towne strain live attenuated vaccine. Birth Defects Orig Artic Ser 20 271-287.
75. SA Plotkin, SE Starr, HM Friedman, et al. (1991) Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 114 525-531.
76. HH Balfour, GW Sach, RC Gehz, et al. (1984) Cytomegalovirus vaccine in renal transplant candidates. Progress report of randomized placebo-controlled double-blind trial. S Michelson, JS Pagano (Eds) Cytomegalovirus: Pathogenesis and Prevention of Human Infection New York: Alan R Riss 289-304.
77. SA Plotkin, R Higgins, JB Kurtz, et al. (1994) Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58 1176-1178.
78. SA Plotkin and ES Huang (1985) Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J Infect Dis 152 395-397.
79. SA Plotkin, RE Weibel, G Alpert, et al. (1985) Resistance of seropositive volunteers to subcutaneous challenge with low-passage human cytomegalovirus. J Infect Dis 151 737-739.
80. SA Plotkin, SE Starr, HM Friedman, et al. (1989) Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 159 860-865.
81. SP Adler, SE Starr, SA Plotkin, et al. (1995) Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 171 26-32.
82. TA Cha, T Edward, W Kemble, et al. (1996) Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 70 78-83.
83. WJ Britt, L Vugler, EJ Butfiloski and EB Stephens (1990) Cell surface expression of human cytomegalovirus (HCMV) gp55–116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64 1079-1085.
84. E Gonczol and SA Plotkin (2001) Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Exp Opin Bio Therapy 1 401-412.
85. CJ Harrison, WJ Britt, NM Chapman, et al. (1995) Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model. J Infect Dis 172 1212-1220.
86. F Hudecz, E Gonczol and SA Plotkin (1985) Preparation of highly purified human cytomegalovirus envelope antigen. Vaccine 3 300-304.
87. E Gonczol, F Hudecz, J Ianacone, et al. (1986) Immune responses to isolated human cytomegalovirus envelope proteins. J Virol 58 661-664.
88. E Gonczol, J Ianacone, WZ Ho, et al. (1990) Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 8 130-136.
89. T Furukawa, E Gonczol, S Starr, et al. (1984) HCMV envelope antigens induce both humoral and cellular immunity in guinea pigs. Proc Soc Exp Biol Med 175 243-250.
90. RR Spaete (1991) A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc 23(Suppl 3), 90-96.
91. GS Marshall, RP Ricciardi, RF Rando, et al. (1990) An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies. J Infect Dis 162 1177-1181.
92. E Gonczol, C de Taisne, G Hirka, et al. (1991) High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity. Vaccine 9 631-637.
93. E Gonczol, K Berensci, S Pincus, et al. (1995) Preclinical evaluation of an ALVAC (canarypox)–human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 13 1080-1085.
94. E Gonczol, K Berencsi, E Kauffman, et al. (1995) Preclinical evaluation of an ALVAC (Canarypox)-human cytomegalovirus glycoprotein B vaccine cadidate: immune response elicited in a prime/boost protocol with the clycoprotein B subunit. Scand J Infect Dis 99 110-112.
95. RR Spaete, A Saxena, PI Scott, et al. (1990) Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne. J Virol 64 2922-2931.
96. JB Wang, SP Adler, S Hempfling, et al. (1996) Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. J Infect Dis 174 387-392.
97. RF Pass, AM Duliege and S Boppana (1995) Immunogenicity of a recombinant CMV gB vaccine. Pediatr Res 37 185A.
98. B Torok-Storb, T Gooley, W Leisenring, et al. (March 5, 1996) Marrow allograft failure is associated with specific cytomegalovirus (CMV) genotypes. (Abstract 33). 6th International Cytomegalovirus Workshop Orange Beach, AL: Perdido Beach Resort
99. D Mitchell, SJ Holmes, RL Burke, et al. (1997) Immunogenicity of a recombinant human cytomegalovirus (CMV) gB vaccine in toddlers. Pediatr Res 41 127A.
100. S Chou and KM Dennison (1991) Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J Infect Dis 163 1229-1234.
101. JF Bale, SJ Petheram, JE Miller and JR Murph (3-5-1996) Cytomegalovirus (CMV) glycoprotein B (gB) genotypes in child care environments. (Abstract 188). 6th International Cytomegalovirus Workshop Orange Beach, AL Abstract: Perdido Beach Resort
102. CY Lo, PCY Woo, SKF Lo, et al. (1996) The frequency and distribution of CMV-enveloped glycoprotein genotypes in bone marrow and renal transplant recipients with CMV disease. (Abstract 126). 6th International Cytomegalovirus Workshop Orange Beach, AL: Perdido Beach Resort
103. C Zhang, H Buchanan, W Andrews, et al. (1999) Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding. J Clin Virol 35 338-342.
104. M Del Val, HJ Schlicht, H Wolkmer, et al. (1991) Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol 65 3641-3646.
105. E McLaughlin-Taylor, H Pande, SJ Forman, et al. (1994) Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8 + virus-specific cytotoxic T lymphocytes. J Med Virol 43 103-110.
106. MR Wills, AJ Carmichael, K Mynard, et al. (1996) The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70 7569-7579.
107. SB Boppana and WJ Britt (1996) Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology 222 293-296.
108. SA Plotkin, M Cadoz, B Meignier, et al. (1995) The safety and use of canarypox vectored vaccines. Dev Biol Stand 84 165-170.
109. SP Adler, SA Plotkin, E Gonczol, et al. (1999) A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 180 843-846.
110. K Berencsi, Z Gyulai, E Gonczol, et al. (2001) A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 183 1171-1179.
111. E Gonczol and SA Plotkin (1990) Progress in vaccine development for prevention of human cytomegalovirus infection. Curr Top Cell Regul 154 255-274.
112. DI Bernstein, MR Schleiss, K Berencsi, et al. (2002) Effect of Previous or Simultaneous Immunization with Canarypox Expressing Cytomegalovirus (CMV) Glycoprotein B (gB) on Response to Subunit gB Vaccine plus MF59 in Healthy CMV-Seronegative Adults. J Infect Dis 185 686-690.
113. Z Wang, C LaRosa, R Maas, et al. (2004) Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J Virol 78 3965-3976.
114. Z Wang, C La Rosa, SF Lacey, et al. (1999) Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J Clin Virol 35 324-331.
115. JA Zaia, JG Sissons, S Riddell, et al. (2000) Status of Cytomegalovirus Prevention and Treatment in 2000. Hematology (Am Soc Hematol Educ Program) 339-355.
116. DJ Diamond, J York, JY Sun, et al. (1997) Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90 1751-1767.
117. L BenMohamed, R Krishnan, J Longmate, et al. (2000) Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. Hum Immunol 61 764-779.
118. H Pande, K Campo, B Tanamachi, et al. (1995) Direct DNA immunization of mice with plasmid DNA encoding the tegument protein pp65 (ppUL83) of human cytomegalovirus induces high levels of circulating antibody to the encoded protein. Scand J Infect Dis Suppl 99 117-120.
119. V Endresz, L Kari, K Berencsi, et al. (1999) Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine 17 50-58.
120. ES Hwang, KB Kwon, JW Park, et al. (1999) Induction of neutralizing antibody against human cytomegalovirus (HCMV) with DNA-mediated immunization of HCMV glycoprotein B in mice. Microbiol Immunol 43 307-310.
121. JC Gonzalez Armas, CS Morello, LD Cranmer and DH Spector (1996) DNA immunization confers protection against murine cytomegalovirus infection. J Virol 70 7921-7928.
122. C Selinsky, C Luke, M Wloch, et al. (2005) A DNA-based vaccine for the prevention of human cytomegalovirus-associated disease. Human Vaccines 1 16-23.
123. S Pepperl, J Munster, M Mach, et al. (2000) Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J Virol 74 6132-6146.
124. ES Tackaberry, AK Dudani, F Prior, et al. (1999) Development of biopharmaceuticals in plant expression systems: cloning, expression and immunological reactivity of human cytomegalovirus glycoprotein B (UL55) in seeds of transgenic tobacco [In Process Citation]. Vaccine 17 3020-3029.
125. MR Schleiss, JC Lacayo, Belkaid, et al. (2007) Preconceptual Administration of an Alphavirus Replicon UL83 (pp65 Homolog) Vaccine Induces Humoral and Cellular Immunity and Improves pregnancy Outcome in the Guinea Pig Model of Congential Cytomegalovirus Infection. J Infect Dis 195 789-798.
126. WJ Britt (1996) Vaccines against human cytomegalovirus : time to test. Trends Microbiol 4 34-38.
127. SA Plotkin (2002) Is there a formula for an effective CMV vaccine. J Clin Virol 25(Suppl 2), S13-S21.
128. SA Plotkin (1999) Vaccination against cytomegalovirus, the changeling demon. Pediatr Infect Dis J 18 313-325.
129. M Schleiss and T Heineman (2005) Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 4 381-406.